Is There Any Difference in Clinical Outcomes Between Transient and Persistent Acute Kidney Injury in ACS Patients after Invasive Treatment?

Acute kidney injury (AKI) following acute coronary syndrome (ACS) is associated with prolonged hospital stay and worse prognosis at followup. However, serum creatinine level increase can either be transient or permanent. At present, retrospective studies show transient AKI patients present similar survival rate to patients with no AKI. The prognostic implications of transient and persistent AKI remain uncertain.   

Una nueva molécula para evitar la nefropatía por contraste

The aim of this sub-study was to assess transient vs. persistent AKI predictors and prognosis in ACS patients randomized to an invasive strategy for the multicenter MATRIX trial (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox).

Primary end point was major adverse cardiovascular events (MACE) at 30 days, defined as all cause death, AMI, stroke, and Net Adverse Cardiovascular Events (NACE) defined as the composite of MACE or BARCIII or V major bleeding. 

Secondary end point included primary end point components and cardiovascular mortality, transient ischemic attack, and target vessel revascularization. It also included ischemic events and bleeding at one year. 

Of a total 8201, AKI occurred in 16.3% of patients. 7.2% was transient and 9.1% persistent. Persistent AKI patients were older and mostly women. 

Read also: One Year Prognosis of Atherosclerotic vs. Non-Atherosclerotic Lesions in MINOCA Patients.

When comparing no AKI patients against persistent AKI patients, the latter showed higher MACE rate at 30 days (P<0.001) and one year (P<0.001). They were also associated to higher cardiovascular mortality rate and bleeding BARC III or V at 30 days (P<0.001) and one year (P<0.001). 

Transient AKI showed no differences in primary or secondary end points at 30 days but did show significant difference at one year as regards MACE (P=0.019) and all-cause and cardiovascular mortality (P=0.011). 

After multivariable analysis, while there was no difference against transient AKI patients, persistent AKI patients had higher MACE rate vs. no AKI patients (P<0.001) as well as higher all-cause mortality (P<0.001) at 30 days.  

Conclusion 

Persistent AKI was associated to higher MACE and NACE rates at 30 days in patients with acute coronary syndrome undergoing invasive treatment. However, this difference was not observed in transient AKI patients.   

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the editorial board of SOLACI.org.

Original Title: Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome.

Reference: Antonio Landi, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...